<b>Background:</b> The non-steroidal mineralocorticoid receptor antagonists (MRAs) are promising treatments in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The gene discussed is NR3C2; the disease is chronic kidney disease.